the University of Illinois. In 1997 he was invited to continue this research in the laboratories of Bristol-Myers Squibb and Ancile Pharmaceuticals. His focus shifted from secondary metabolism to primary metabolism with the establishment of the first metabolomics platform in America at Paradigm Genetics from 2000 to 2002, and in 2003, he founded two metabolomics-based companies: Metabolon, Inc. (a company that has focused platform technologies on human health care) and Metabolic Analyses, Inc. (a company that has focused on the informatics issues associated with metabolomics). Dr. Beecher compiled the first human metabolome in 2002 at Metabolic Analyses and has been working toward the integration of metabolomic, proteomic, transcriptomic, and genomic data. In addition to his primary appointment at the University of Michigan, Dr. Beecher serves as an adjunct professor at George Mason University and is an affiliate of the National Institute of Statistical Sciences. He holds many patents and publications in the areas of metabolomics and natural products chemistry.


Ellen Wright Clayton, M.D., J.D., received a bachelor’s degree from Duke, a master’s degree from Stanford, her law degree from Yale, and her medical degree from Harvard. A member of the Vanderbilt faculty since 1988, she is currently the Rosalind E. Franklin Professor of Genetics and Health Policy and co-director of the Center for Biomedical Ethics and Society at the Vanderbilt University Medical Center. She is also professor of pediatrics and professor of law. At Vanderbilt, she directs the Law Emphasis Program and teaches in the patient, profession, and society course in the medical school and teaches the interdisciplinary course in bioethics and law in four schools of the university. Dr. Clayton has focused primarily on issues surrounding the ethical, legal, and social implications of advances in genetics and genomics as both a scholar and a policy maker. She has served on Tennessee’s Genetics Advisory Council since the early 1990s, has participated in numerous policy and academic groups that have considered newborn screening, and is currently conducting research on the impact of false positive results in newborn screening. She has been very involved with the Human Genome Project in the United States, serving as a member of the National Advisory Council for Human Genome Research and more recently as co-chair of the Ethical, Legal, and Social Implications Working Group of the International Haplotype Mapping Project. She has also been very involved in ethical issues raised by genetics and genomics research, working with investigators and deliberative bodies around the world. She has been instrumental in the development of Vanderbilt’s DNA biobank and is currently co-chair of the Consent and Community Consultation Working Group of the eMERGE consortium, which is studying the use of electronic medical records in genome-wide association studies. She has also written about a variety of issues regarding children’s and women’s health.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement